Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have
demonstrated significant anti-myeloma effects in preclinical lab and animal studies. The
goal of this phase I trial is to evaluate in patients with relapsed or refractory multiple
myeloma the safety, toxicity profile and tolerability of ABT-888 (Veliparib) administered on
a schedule including twice daily oral dosing for 14 days followed by 1 week rest in
combination with standard dosing of Bortezomib.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society